Infinity Announces Presentations On IPI-549 At Upcoming Immuno-Oncology Meeting
CAMBRIDGE, Mass., Sept. 6, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new preclinical data as well as early clinical data from an ongoing Phase 1 study will be presented for IPI-549, an immuno-oncology development candidate that selectively inhibits PI3K-gamma, during the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival taking place September 25-28, 2016, in New York City.
The following two presentations will take place during the poster session being held on Monday, September 26, from 5:15 p.m. – 7:45 p.m. ET:
Title: IPI-549-01: A Phase 1/1b first-in-human study of IPI-549, a PI3K-gamma inhibitor, as monotherapy and in combination with an anti-PD1 antibody in subjects with advanced solid tumors
Poster Board: B070
Presentation Time: Monday, September 26, 6:15 p.m. – 7:15 p.m. ET
Title: The PI3K-gamma inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment
Poster Board: B032
Presentation Time: Monday, September 26, 6:15 p.m. – 7:15 p.m. ET
About IPI-549
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. In preclinical studies, IPI-549 inhibits immune-suppressive macrophages within the tumor microenvironment, whereas other immunotherapies such as checkpoint modulators more directly target immune effector cell function. As such, IPI-549 may have the potential to treat a broad range of solid tumors and represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors.
IPI-549 is an investigational compound and its safety and efficacy has not been evaluated by the U.S. Food and Drug Administration or any other health authority.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including those regarding the company's expectations about the timing and type of data presentations and the therapeutic potential of PI3K-gamma inhibition and of IPI-549, alone or in combination with other agents. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations, including, for example, that there is no guarantee that IPI-549 will successfully complete necessary preclinical and clinical development phases, or gain regulatory approval and other risks described in greater detail under the caption "Risk Factors" included in Infinity's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2016, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Jaren Irene Madden, Senior Director,
Investor Relations and Corporate Communications
617-453-1336 or [email protected]
Logo - http://photos.prnewswire.com/prnh/20150916/267365LOGO
SOURCE Infinity Pharmaceuticals, Inc.
Share this article